|
Home | Your Profile | Search | About Us | Pricing | Disclaimer |
|
|
|
 |
Home |  |
|
Outsourcing Reports | |
|
Outsourcing Showcase | |
 |
Reports Store |  |
|
Outsourcing Directory | |
|
Events | |
|
Advertising | |
|
News | |
| | Help |
8 Items, CDN $ 6695 |
Go Back  |
|||
Abstract 150 Pages The report "Asia Pacific Biotechnology Market (2007-2010)” provides an updated and detailed overview of the Asia-Pacific Biotechnology industry. It examines the emerging trends and provides exclusive forecasts and segment-wise snapshots of the Biotechnology industry in the region. The report also presents the information regarding the government policies on Biotechnology and region-wise Bioclusters in the Asia-Pacific countries. Key Findings § Growing at an estimated CAGR of 11.23% between 2004 and 2006, the expected value of Asia-Pacific Biotechnology market by 2006 end is more than US$ 39.16 Billion. § Japan, China, and Taiwan are the largest Biotechnology markets in the Asia-Pacific region that had a combined market share of nearly 76% in 2006. § The Asia-pacific region will emerge as a key destination for clinical trials & stem cell research. § Biotechnology will play an important role in agriculture sector by developing large number of genetically modified (GM) crops. § Biopharma industry, comprising of vaccines, therapeutics, diagonostics and other products, will emerge as a major segment of the Asia-Pacific Biotech industry. § The Biotechnology industry in the Asia-pacific region is largely dependent on the government with very little private participation in most of the countries. § Lack of venture funding remains a major challenge for Asia-Pacific Biotechnology companies. § The Contract Research industry in India could reach as high as US$ 270 Million by 2009. § The Japanese Government, which was earlier accused of shielding its domestic companies, has now opened its doors for foreign investment. § Opaque government policies and regulations in China are acting as a major hurdle for foreign participation in the biotechnology market. Key Issues and Facts The research report also addresses the issues and facts that are critical to your success in the emerging Biotechnology indutry in Asia-Pacific: § What are the market trends in the Asia-Pacific Biotechnology industry? § A insight into the Biotechnology industries of Japan, China, India, Korea, Australia, Taiwan, New Zealand, and Singapore. § The role played by the goverments in Asia-Pacific in promoting their respective Biotech industries. § An overview of Bioclusters in the Asia-Pacific Biotechnology industry. § Key sectors in the Asia-Pacific biotechnology industry. § Course of market growth for the next 5 years. § Opportunities that can be leveraged by the Asia-Pacific Biotechnology industry. § Forces that are working in favor of Asia-Pacific Biotechnology industry. § Issues confronted by the Asia-Pacific Biotechnology industry. Research Methodology Information Sources Information has been sourced from various authentic sources, like books, newspapers, trade journals and white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to more than 3000 paid databases. Analysis Methods The analysis methods include Ratio Analysis, Historical Trend Analysis, Linear Regression Analysis (using software tools), Judgmental Forecasting, and Cause and Effect Analysis. Table of Contents 1. Analyst View 2. Research Overview 3. Biotechnology Industry Overview 3.1 Market Overview 3.2 Venture Financing Capital 3.3 Mergers & Acquisitions 3.4 US - Growing & Leading the Market 3.5 Europe - Sustained Recovery 3.6 Asia-Pacific - Most Promising Region 4. Asia-Pacific Biotechnology Market 4.1 Introduction 4.2 Market Size 4.3 Market Segmentation 5. Asia-Pacific Biotechnology Market by Country 5.1 Japan 5.1.1 Market Overview 5.1.2 Market Segmentation 5.1.3 Industry Overview 5.1.4 Government Role 5.1.5 Bio-clusters 5.1.6 Opportunities & Challenges 5.1.6.1 Opportunities 5.1.6.1.1 Pharmaceutical Sector 5.1.6.1.2 Medical Devices Market 5.1.6.1.3 In Vitro Diagnostics Market 5.1.6.1.4 Agriculture 5.1.6.1.5 Food & Bioprocessing Industry 5.1.6.1.6 Biotools Market 5.1.6.1.7 Bioinformatics 5.1.6.1.8 Environment Market 5.1.6.2 Challenges 5.1.6.2.1 Heavy Burden on the Government 5.1.6.2.2 Lack of Bioventures in Japan 5.1.6.2.3 Lack of Integration between Academic Research & Industry 5.1.6.2.4 Regulatory System 5.1.6.2.5 Laggard in Certain Areas 5.1.7 Future Outlook (2007-2009) 5.2 China 5.2.1 Market Overview 5.2.2 Market Segmentation 5.2.3 Industry Overview 5.2.4 Government Role 5.2.5 Bio-clusters 5.2.6 Opportunities & Challenges 5.2.6.1 Opportunities 5.2.6.1.1 Biopharmaceuticals 5.2.6.1.2 New Drug Development 5.2.6.1.3 Lab Supplies 5.2.6.1.4 Bio-services 5.2.6.1.5 Chemicals & Enzymes 5.2.6.1.6 Agri & Aquaculture 5.2.6.1.7 Environmental Products & Services 5.2.6.2 Challenges 5.2.6.2.1 Overdependence on the Government 5.2.6.2.2 Lack of Coordination between Divisions & Researchers 5.2.6.2.3 Long-term Acceptance of Biotechnology Products 5.2.6.2.4 Regulations Restricting Foreign Investment 5.2.6.2.5 Intellectual Property & Underdeveloped Capital Market 5.2.6.2.6 Lack of Management & Investor Seasoning 5.2.7 Future Outlook (2007-2009) 5.3 India 5.3.1 Market Analysis 5.3.2 Market Segmentation 5.3.3 Government Role 5.3.4 Bio-clusters 5.3.5 Opportunities & Challenges 5.3.5.1 Opportunities 5.3.5.1.1 Outsourcing of Preliminary Research 5.3.5.1.2 Off-patent Drug 5.3.5.1.3 Clinical Trial Market 5.3.5.1.4 Bioinformatics 5.3.5.1.5 Stem Cell Research 5.3.5.1.6 Agricultural Biotechnology 5.3.5.1.7 Biofuel 5.3.5.1.8 Biofertilizers/Biopesticides 5.3.5.2 Challenges 5.3.5.2.1 Lack of IPR (Intellectual Property Rights) Regime 5.3.5.2.2 Time to Market 5.3.5.2.3 Seed Funding 5.3.5.2.4 Synergy between Stakeholders 5.3.5.2.5 High Innovative Drug Cost 5.3.5.2.6 Regulatory Issues 5.3.6 Future Outlook (2007-2010) 5.4 Australia 5.4.1 Market Analysis 5.4.2 Market Segmentation 5.4.3 Industry Overview 5.4.4 Government Role 5.4.5 Bio-clusters 5.4.6 Opportunities & Challenges 5.4.6.1 Opportunities 5.4.6.1.1 Agrobiotechnology 5.4.6.1.2 Health 5.4.6.1.3 Environmental Biotechnology 5.4.6.1.4 Industrial Biotechnology 5.4.6.1.5 Stem Cell Research 5.4.6.2 Challenges 5.4.6.2.1 Lack of Commercial Skills 5.4.6.2.2 Lack of Commercial Finesse 5.4.6.2.3 Inability to Market a Product 5.4.6.2.4 Ethical & Consumer Issues 5.4.6.2.5 Cash 5.4.7 Future Outlook (2007-2010) 5.5 Taiwan 5.5.1 Market Analysis 5.5.2 Market Segmentation 5.5.3 Market Overview 5.5.4 Government Role 5.5.5 Bio-clusters 5.5.6 Opportunities & Challenges 5.5.6.1 Opportunities 5.5.6.1.1 Bioinformatics 5.5.6.1.2 Pharmaceuticals 5.5.6.1.3 Medical Devices 5.5.6.1.4 New Emerging Biotech Sectors 5.5.6.2 Challenges 5.5.6.2.1 Inadequate Funding for Research 5.5.6.2.2 Legislations of Certain Laws 5.5.6.2.3 Weak Connection between Laboratories & Factories 5.5.6.2.4 Limited Competition Ability 5.5.6.2.5 Inadequate Understanding of Biotechnology 5.5.6.2.6 Traditional Nursery Companies and GMO Business 5.5.6.2.7 Need for International Co-operation 5.5.7 Future Outlook (2007-2010) 5.6 South Korea 5.6.1 Market Analysis 5.6.2 Market Segmentation 5.6.3 Market Overview 5.6.4 Government Role 5.6.5 Bio-clusters 5.6.6 Opportunities & Challenges 5.6.6.1 Opportunities 5.6.6.1.1 International Markets for Drugs 5.6.6.1.2 Embryo Cell Cloning & Human Stem Cell Development 5.6.6.1.3 Developing a Large Pool of Bio-ventures 5.6.6.1.4 Bioinformatics 5.6.6.1.5 Environmental Biotechnology 5.6.6.1.6 Nanobiotechnology 5.6.6.2 Challenges 5.6.6.2.1 Dr. Hwang Controversy 5.6.6.2.2 Non-Tariff Barriers to Potential Market Entrants 5.6.6.2.3 Bioethics & Biosafety 5.6.6.2.4 Complicated Distribution Channels 5.6.6.2.5 Lack of Clinical Testing Capabilities 5.6.6.2.6 International Patents 5.6.6.2.7 Weak Knowledge Base 5.6.6.2.8 Inadequate Local Venture Capital or Funds 5.6.7 Future Outlook (2007-2010) 5.7 New Zealand 5.7.1 Market Analysis 5.7.2 Market Segmentation 5.7.3 Market Overview 5.7.4 Government Role 5.7.5 Bio-clusters 5.7.6 Opportunities & Challenges 5.7.6.1 Opportunities 5.7.6.1.1 Agriculture 5.7.6.1.2 Increased Venture Capital (VC) & Private Equity (PE) Funding 5.7.6.1.3 Environment Biotechnology 5.7.6.1.4 Industrial Biotechnology 5.7.6.1.5 Nanotechnology 5.7.6.2 Challenges 5.7.6.2.1 Lack of Support for a Long-term Direction 5.7.6.2.2 Lack of Human Resource 5.7.6.2.3 Commercial Vulnerability 5.7.6.2.4 Reliance on International Companies for Technologies 5.7.6.2.5 Negative Perceptions held by Potential Overseas Investors 5.7.7 Future Outlook (2007-2010) 5.8 Singapore 5.8.1 Market Analysis 5.8.2 Market Overview 5.8.3 Government Role 5.8.4 Bio-clusters 5.8.5 Opportunities & Challenges 5.8.5.1 Opportunities 5.8.5.1.1 Biopharmaceuticals 5.8.5.1.2 Clinical Trials Hub 5.8.5.1.3 Bioinformatics 5.8.5.1.4 Nanotechnology 5.8.5.1.5 Stem Cell Research 5.8.5.1.6 Enabling Technologies 5.8.5.1.7 Intellectual Property 5.8.5.2 Challenges 5.8.5.2.1 Venture Funding 5.8.5.2.2 Human Resources 5.8.5.2.3 Low Rate of Survival for Biotechnology Startups 5.8.5.2.4 Lack of Understanding of Life Sciences Ingredients 5.8.5.2.5 Inability to Respond to Changes in the Industry 5.8.6 Future Outlook (2007-2009) 6. Industry Analysis 6.1 Key Driving Forces 6.1.1 Strong G4Government Support 6.1.2 Human Resources 6.1.3 Bio-diversity 6.1.4 Infrastructure 6.1.5 Low Cost 6.2 Opportunities 6.2.1 Contract Research/Manufacturing 6.2.2 Vaccines 6.2.3 Generics 6.2.4 Biofuel 6.2.5 Stem Cell Research 6.2.6 Nanotechnology 6.2.7 Bioremediation 6.2.8 Bioinformatics 6.3 Challenges 6.3.1 Lack of IPR Regime 6.3.2 Lack of Private Participation 6.3.3 Lack of Bioventures 6.3.4 Seed Funding 6.3.5 Inability to Take a Product from Invention to the Market 6.3.6 Ethical & Safety Issues 6.4 Future Outlook - 2009 6.4.1 Increased Government Support 6.4.2 Role of Private Sector 6.4.3 Improved Intellectual Property Regime 6.4.4 Mergers & Acquisitions 6.4.5 Infrastructure Improvement 6.4.6 Sustained Growth in Revenues till 2009 6.4.7 Japan, China, & Taiwan to Dominate the Market 7. Competitive Landscape 7.1 Invitrogen Corporation 7.2 Takara Holdings, Inc. 7.3 CSL Limited 7.4 Biota Holdings Limited 7.5 GlaxoSmithKline Plc | |||
Using the Site Privacy & Security Statement
Advertise with us Directory Guide
CanBiotech Newsletters
© 2000-2010 CanBiotech™ Inc.